Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.68
- Piotroski Score 3.00
- Grade N/A
- Symbol (BIOSU)
- Company BioPlus Acquisition Corp.
- Price $10.80
- Changes Percentage (-0.37%)
- Change -$0.04
- Day Low $10.80
- Day High $10.84
- Year High $11.56
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/30/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $5.16 M
Income Statement
Quarterly
Annual
Latest News of BIOSU
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Aroa Biosurgery Limited (ASX:ARX): Is Breakeven Near?
Aroa Biosurgery Limited is close to achieving profitability, expecting to break even in 2026. Analysts project a 56% annual growth rate until then. The company operates debt-free, reducing investment ...
By Yahoo! Finance | 1 week ago -
Aroa Biosurgery And 2 Other ASX Penny Stocks To Watch
The Australian market saw a downturn, but interest remains in exploring penny stocks for growth potential. Aroa Biosurgery, Plenti Group, and Praemium are standout penny stock options with financial i...
By Yahoo! Finance | 4 weeks ago -
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Investors are often drawn to unprofitable companies with potential for growth. Aroa Biosurgery's cash burn rate is analyzed, showing a 2.1-year cash runway. Despite increasing cash burn, positive reve...
By Yahoo! Finance | 4 months ago
